当前位置: X-MOL 学术Lancet Child Adolesc. Health › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Characteristics of children with invasive pneumococcal disease eligible for the 1+1 compared with the 2+1 PCV13 infant immunisation schedule in England: a prospective national observational surveillance study
The Lancet Child & Adolescent Health ( IF 19.9 ) Pub Date : 2024-09-24 , DOI: 10.1016/s2352-4642(24)00193-7
Fariyo Abdullahi MSc, Marta Bertran MSc, Joshua C D'Aeth PhD, Seyi Eletu PhD, Yung-Wai Chan MSc, Nick J Andrews PhD, David J Litt PhD, Prof Mary E Ramsay FFPH, Prof Shamez N Ladhani PhD

On Jan 1, 2020, the UK transitioned from a 2+1 to a 1+1 national infant immunisation schedule with the 13-valent pneumococcal conjugate vaccine (PCV13). We assessed whether the 1+1 PCV13 schedule had any impact on incidence, disease characteristics, or outcomes after invasive pneumococcal disease (IPD) in eligible children aged 0–3 years.

中文翻译:


英格兰符合 1+1 条件的侵袭性肺炎球菌疾病儿童与 2+1 PCV13 婴儿免疫接种计划的特征比较:一项前瞻性全国观察性监测研究



2020 年 1 月 1 日,英国使用 13 价肺炎球菌结合疫苗 (PCV13) 从 2+1 过渡到 1+1 国家婴儿免疫接种计划。我们评估了 1+1 PCV13 方案是否对符合条件的 0-3 岁儿童侵袭性肺炎球菌病 (IPD) 后的发病率、疾病特征或结局有任何影响。
更新日期:2024-09-24
down
wechat
bug